EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinical Performance of an N-Terminal Pro-B-Type Natriuretic Peptide Assay in Acute Heart Failure Diagnosis

Lori B Daniels, Patience Ajongwen, Robert H Christenson, Carol L Clark, Deborah B Diercks, Gregory J Fermann, Sharon E Mace, Simon A Mahler, Peter S Pang, Zubaid Rafique iD, Michael S Runyon, James Tauras und 1 weitere

The Journal of Applied Laboratory Medicine · 2025

DOI: 10.1093/jalm/jfae107 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Applied Laboratory Medicine, 2025. Verfasst von Lori B Daniels und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Diego, La Jolla, CA, United States. Hauptthemen laut MEDLINE: Natriuretic Peptide, Brain, Heart Failure, Peptide Fragments. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Ortho Clinical Diagnostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We evaluated the Vitros® Immunodiagnostic Products N-terminal pro B-type natriuretic peptide (NT-proBNP) II assay for aiding in diagnosis of heart failure (HF) in patients with acute dyspnea.

Methods

Serum concentrations of NT-proBNP were measured in patient samples from 20 emergency departments across the United States. Study endpoints included sensitivity, specificity, likelihood ratios, and predictive values for diagnosis of acute HF according to age-stratified cutoffs (450, 900, and 1800 pg/mL), and a rule-out age-independent cutoff (300 pg/mL). Additional measures were area under the curve (AUC) for receiver operating characteristic (ROC) curves. Results were also interpreted in patient subgroups with relevant comorbidities, and gray zone/intermediate assay values.

Results

Of 2200 patients, 1095 (49.8%) were diagnosed with HF by clinical adjudication. Sensitivity and specificity for Vitros NT-proBNP II ranged from 84.0% to 92.1%, and 81.4% to 86.5%, respectively, within and across age groups, and positive predictive values were 80.4% to 85.7%. Using the rule-out cutoff, the negative predictive value was 97.9%, with a negative likelihood ratio of 0.02. In subgroups with comorbidities potentially affecting NT-proBNP concentrations, sensitivities ranged from 82.6% to 89.5%, and AUCs for ROC curves were 0.899 to 0.915.

Conclusions

The Vitros NT-proBNP II assay demonstrated excellent clinical performance using age-stratified cutoffs along with other clinical information for supporting diagnosis of HF, and can rule out HF with a high negative predictive value using the age-independent cutoff. The assay retained utility in patient subgroups with conditions that influence NT-proBNP concentration, and for those with gray zone results. ClinicalTrials.gov Registration Number NCT03548909.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Natriuretic Peptide, BrainHeart FailurePeptide FragmentsHumansFemaleMaleAgedMiddle AgedROC CurveBiomarkersSensitivity and SpecificityAged, 80 and overAcute DiseasePredictive Value of TestsEmergency Service, HospitalArea Under CurveDyspneaAdultUnited StatesImmunoassay

Substanzen

Natriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Biomarkers

Autor:innen und Institutionen

  • Department of Medicine, University of California, San Diego, La Jolla, CA, United States.
  • Department of Biostatistics & Clinical Data Management/Science, QuidelOrtho Corporation, Raritan, NJ, United States.
  • Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, United States.
  • Department of Emergency Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, MI, United States.
  • Department of Emergency Medicine, UT Southwestern Medical Center, Dallas, TX, United States.
  • Department of Emergency Medicine, University of Cincinnati, Cincinnati, OH, United States.

ORCID-Profile: Zubaid Rafique

Förderung

  • Ortho Clinical Diagnostics

Zitieren

APA

Daniels, L. B., Ajongwen, P., Christenson, R. H., Clark, C. L., Diercks, D. B., Fermann, G. J., Mace, S. E., Mahler, S. A., Pang, P. S., Rafique, Z., Runyon, M. S., Tauras, J., & deFilippi, C. R. (2025). Clinical Performance of an N-Terminal Pro-B-Type Natriuretic Peptide Assay in Acute Heart Failure Diagnosis. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfae107

Vancouver

Daniels LB, Ajongwen P, Christenson RH, Clark CL, Diercks DB, Fermann GJ, et al. Clinical Performance of an N-Terminal Pro-B-Type Natriuretic Peptide Assay in Acute Heart Failure Diagnosis. The Journal of Applied Laboratory Medicine. 2025. doi:10.1093/jalm/jfae107

BibTeX
@article{Daniels2025,
  author = {Daniels, Lori B and Ajongwen, Patience and Christenson, Robert H and Clark, Carol L and Diercks, Deborah B and Fermann, Gregory J and Mace, Sharon E and Mahler, Simon A and Pang, Peter S and Rafique, Zubaid and Runyon, Michael S and Tauras, James and deFilippi, Christopher R},
  title = {Clinical Performance of an N-Terminal Pro-B-Type Natriuretic Peptide Assay in Acute Heart Failure Diagnosis},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2025},
  doi = {10.1093/jalm/jfae107}
}
Kostenlos starten →